No Data
No Data
Tibet Rhodiola Pharmaceutical Holding (600211.SH) announced a semi-annual equity distribution for the year 2024: a dividend of 0.967 yuan per share. The record date for the equity is August 28th.
Tibet Rhodiola Pharmaceutical Holding (600211.SH) released its 2024 interim equity distribution implementation announcement, and this profit distribution is based on ...
Tibet Rhodiola Pharmaceutical Holding Semi-annual Report for 2023
Summary of Tibet Rhodiola Pharmaceutical Holding's H1 2024 report.
Tibet Rhodiola Pharmaceutical Holding (600211.SH): Net income in the first half of the year was 623 million yuan, a year-on-year increase of 4.57%. The plan is to distribute dividends of 9.67 yuan per share.
On August 13th, GeLongHui reported on Tibet Rhodiola Pharmaceutical Holding(600211.SH)'s half-year report for 2024. The report period realized revenue of 1.615 billion yuan, a year-on-year decrease of 11.29%, and a net profit attributable to shareholders of listed companies of 0.623 billion yuan, a year-on-year increase of 4.57%. Excluding non-recurring gains and losses, the net profit attributable to shareholders of listed companies was 0.524 billion yuan, a year-on-year decrease of 9.85%. Basic earnings per share were 1.93 yuan. Based on the company's current operational situation, the company plans to distribute profits based on the total share capital that participants can receive on the date of registration of equity distribution plan. Board of directors will distribute 1.05 yuan cash dividend per share to all shareholders for every 10 shares held
Tibet Rhodiola Pharmaceutical Holding (600211.SH): There is currently no specific plan for overseas sales of their main product, Xinhuosu.
On July 11th, Gloden Investment Network received inquiries from an investor on the investor Q&A platform regarding Tibet Rhodiola Pharmaceutical Holding (600211.SH), asking: "Does the company's main product have the potential and plan to expand overseas? Are there products with similar efficacy overseas?" The company replied that the main product, Xinhuosu, does not currently have a specific plan for overseas sales, but the product Imdur is sold overseas. Public information shows that Xinhuosu and Nesiritide from abroad are both products used for the treatment of acute decompensated heart failure.
Tibet Rhodiola Pharmaceutical Holding (600211.SH): The new production line for Xin Huosu is expected to commence formal production in the second half of the year after registration approval.
According to the investor relations activity records disclosed by Tibet Rhodiola Pharmaceutical Holding (600211.SH) on July 10th, the new production line of Xinhuosu is expected to be put into formal production after registering and approving in the second half of the year, and the total production capacity will reach 15 million units per year. The total investment of the production line is about 0.14 billion yuan. The company is expected to complete the transfer and consolidation next year according to the accounting standards and actual situations, and then depreciate or amortize it for 12 years, which will not have a significant impact on the company's profits.
No Data
No Data